{"id":"https://openalex.org/W2946858147","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.5502","title":"Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).","display_name":"Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2946858147","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.5502","mag":"2946858147"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.5502","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.5502","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.5502","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076246054","display_name":"Panagiotis A. Konstantinopoulos","orcid":"https://orcid.org/0000-0002-1032-1479","observed_orcids":["https://orcid.org/0000-0002-1032-1479"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Panagiotis A. Konstantinopoulos","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060953135","display_name":"Joyce F. Liu","orcid":"https://orcid.org/0000-0003-3888-3972","observed_orcids":["https://orcid.org/0000-0003-3888-3972"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joyce F. Liu","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103784760","display_name":"Weixiu Luo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weixiu Luo","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030257115","display_name":"Carolyn N. Krasner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carolyn N. Krasner","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067516923","display_name":"Jeffrey Joseph Ishizuka","orcid":"https://orcid.org/0000-0002-4271-7312","observed_orcids":["https://orcid.org/0000-0002-4271-7312"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey Joseph Ishizuka","raw_affiliation_strings":["Brigham and Women's Hospital, Jamaica Plain, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Jamaica Plain, MA;","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110564493","display_name":"Allison Ann Gockley","orcid":"https://orcid.org/0000-0002-4750-5589","observed_orcids":["https://orcid.org/0000-0002-4750-5589"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allison Ann Gockley","raw_affiliation_strings":["Brigham and Women's Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Boston, MA;","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076088266","display_name":"Mary Kathleen Buss","orcid":"https://orcid.org/0000-0002-0410-9463","observed_orcids":["https://orcid.org/0000-0002-0410-9463"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary K. Buss","raw_affiliation_strings":["Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037937774","display_name":"Susana M. Campos","orcid":"https://orcid.org/0000-0001-9672-473X","observed_orcids":["https://orcid.org/0000-0001-9672-473X"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susana M. Campos","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062818691","display_name":"Elizabeth H. Stover","orcid":"https://orcid.org/0000-0002-6578-3216","observed_orcids":["https://orcid.org/0000-0002-6578-3216"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elizabeth Stover","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032378308","display_name":"Alexi A. Wright","orcid":"https://orcid.org/0000-0002-9776-7114","observed_orcids":["https://orcid.org/0000-0002-9776-7114"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexi A. Wright","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053081492","display_name":"Whitfield B. Growdon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Whitfield Board Growdon","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003082405","display_name":"Jennifer D. Curtis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Curtis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103764087","display_name":"Ariana Peralta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ariana Peralta","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039767641","display_name":"Patrice Basada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrice Basada","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023682024","display_name":"Roxanne Quinn","orcid":"https://orcid.org/0000-0002-4877-6188","observed_orcids":["https://orcid.org/0000-0002-4877-6188"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roxanne Quinn","raw_affiliation_strings":["Dana\u2013Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana\u2013Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007568796","display_name":"Kathryn P. Gray","orcid":"https://orcid.org/0000-0003-3287-3685","observed_orcids":["https://orcid.org/0000-0003-3287-3685"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathryn P. Gray","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089955620","display_name":"Richard T. Penson","orcid":"https://orcid.org/0000-0002-8091-8588","observed_orcids":["https://orcid.org/0000-0002-8091-8588"]},"institutions":[{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard T. Penson","raw_affiliation_strings":["Harvard Medical School, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Harvard Medical School, Boston, MA;","institution_ids":["https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110158644","display_name":"Stephen A. Cannistra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen A. Cannistra","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA;","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046031005","display_name":"Gini F. Fleming","orcid":"https://orcid.org/0000-0003-2845-4023","observed_orcids":["https://orcid.org/0000-0003-2845-4023"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gini F. Fleming","raw_affiliation_strings":["The University of Chicago Medicine, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Chicago Medicine, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058249824","display_name":"Ursula A. Matulonis","orcid":"https://orcid.org/0000-0002-3103-6992","observed_orcids":["https://orcid.org/0000-0002-3103-6992"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ursula A. Matulonis","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"5502","last_page":"5502"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.7562999725341797,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.7562999725341797,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.23569999635219574,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11369","display_name":"Genetic factors in colorectal cancer","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/avelumab","display_name":"avelumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.8980000019073486},{"id":"https://openalex.org/keywords/recurrent-endometrial-cancer","display_name":"recurrent endometrial cancer","score":0.8370000123977661},{"id":"https://openalex.org/keywords/microsatellite-instability","display_name":"microsatellite instability","score":0.8740000128746033},{"id":"https://openalex.org/keywords/pole-mutation","display_name":"POLE mutation","score":0.8640000224113464},{"id":"https://openalex.org/keywords/microsatellite-stability","display_name":"microsatellite stable","score":0.8379999995231628},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.9100000262260437},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7089999914169312},{"id":"https://openalex.org/keywords/mismatch-repair-proteins","display_name":"mismatch repair proteins","score":0.7089999914169312},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.722000002861023},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9940000176429749},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.7300000190734863},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.3720000088214874},{"id":"https://openalex.org/keywords/two-stage-adaptive-design","display_name":"two-stage adaptive design","score":0.4869999885559082}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7882986068725586},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.776358962059021},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5730205178260803},{"id":"https://openalex.org/C2779767149","wikidata":"https://www.wikidata.org/wiki/Q488212","display_name":"Microsatellite instability","level":5,"score":0.5698594450950623},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5395021438598633},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5215392112731934},{"id":"https://openalex.org/C2777088508","wikidata":"https://www.wikidata.org/wiki/Q944777","display_name":"Endometrial cancer","level":3,"score":0.4482444226741791},{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.43410611152648926},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4165516495704651},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4074927568435669},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.25948190689086914},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1810641586780548},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.15887251496315002},{"id":"https://openalex.org/C61320498","wikidata":"https://www.wikidata.org/wiki/Q265193","display_name":"Microsatellite","level":4,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C180754005","wikidata":"https://www.wikidata.org/wiki/Q80726","display_name":"Allele","level":3,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.5502","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.5502","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.5502","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2810746091","https://openalex.org/W2891755198","https://openalex.org/W2970410478","https://openalex.org/W4313229014","https://openalex.org/W3018059490","https://openalex.org/W4396621269","https://openalex.org/W4379283474","https://openalex.org/W4403250789","https://openalex.org/W3088447833","https://openalex.org/W2946917791"],"abstract_inverted_index":{"5502":[0],"Background:":[1],"This":[2],"non-randomized":[3],"phase":[4],"2":[5,97,278],"study":[6,154],"evaluated":[7],"the":[8,34,43,105,128,172,182,203,207,222,240,259,301,338,366],"PD-L1":[9,327,361],"inhibitor":[10],"avelumab":[11,147,357],"in":[12,42,112,155,181,221,239,311,323,360,365,372],"two":[13],"cohorts":[14],"of":[15,27,29,33,46,58,133,152,160,178,210,215,305,316],"EC:":[16],"i)":[17],"MSI/":[18],"POLE":[19,47],"cohort":[20,51,168,205,224,368],"including":[21,52],"ECs":[22,53],"with":[23,54,131,262,313,356],"immunohistochemical":[24],"(IHC)":[25],"loss":[26],"expression":[28,57],"at":[30,86,171,337],"least":[31],"one":[32],"mismatch":[35],"repair":[36],"(MMR)":[37],"proteins":[38],"and/or":[39],"documented":[40],"mutation":[41],"exonuclease":[44],"domain":[45],"and":[48,71,82,191,195,230,255,275,297,322],"ii)":[49],"MSS":[50,167,183,350],"normal":[55],"IHC":[56],"all":[59,234],"MMR":[60],"proteins.":[61],"Methods:":[62],"Eligibility":[63],"criteria":[64],"included":[65],"measurable":[66],"disease,":[67],"unlimited":[68],"prior":[69,317],"therapies,":[70],"any":[72],"EC":[73,342],"histology.":[74],"Co-primary":[75],"endpoints":[76],"were":[77,110,117,164,231,293,309,326,369],"confirmed":[78],"objective":[79],"response":[80,193,358],"(OR)":[81],"progression-free":[83],"survival":[84],"rate":[85,197,249,268],"6":[87,256,287,306],"months":[88],"(PFS6).":[89],"Avelumab":[90],"10":[91],"mg/kg":[92],"IV":[93],"was":[94,169],"given":[95],"every":[96],"weeks":[98],"until":[99],"progression":[100],"or":[101,120,143],"unacceptable":[102],"toxicity.":[103],"In":[104,300,341],"1st":[106,173],"stage,":[107],"16":[108,179],"pts":[109,163,180,220,238,244,257,261,281,312,343],"enrolled":[111],"each":[113,156],"cohort;":[114],"if":[115,138],"there":[116,139,292],"\u22652":[118,121],"ORs":[119,142,212],"PFS6":[122,145,192,196,265,307],"responses,":[123,146],"accrual":[124,214],"would":[125,148],"continue":[126],"to":[127,176,353],"2nd":[129],"stage":[130,174],"enrollment":[132],"19":[134],"additional":[135],"pts.":[136,218],"Overall,":[137],"are":[140],"\u22654":[141],"\u22658":[144],"be":[149,335,354],"considered":[150],"worthy":[151],"further":[153,381],"cohort.":[157],"Results:":[158],"As":[159],"12/2018,":[161],"33":[162],"enrolled.":[165],"The":[166],"closed":[170],"due":[175],"futility;":[177],"cohort,":[184,242,303],"only":[185,216],"1":[186],"pt":[187],"exhibited":[188,245,264],"an":[189],"OR":[190,246,248],"[ORR":[194],"6.25%":[198],"(95%":[199,252,270],"CI":[200,253,271],"0.16%-30.2%)].":[201],"Conversely,":[202],"MSI/POLE":[204,223,241,302,346,367],"reached":[206],"primary":[208],"endpoint":[209],"4":[211,243,260,273],"after":[213],"17":[217],"Two":[219],"did":[225],"not":[226],"initiate":[227],"protocol":[228],"therapy":[229,318],"excluded":[232],"from":[233],"analyses.":[235],"Of":[236],"15":[237],"[1CR+3PRs,":[247],"(ORR)":[250],"26.7%":[251],"7.8%-55.1%)]":[254],"(including":[258],"OR)":[263],"responses":[266,308],"[PFS6":[267],"40.0%":[269],"16.3%-66.7%)],":[272],"ongoing":[274],"3":[276],"approaching":[277],"yrs.":[279],"Twenty-two":[280],"(71%)":[282],"reported":[283,336],"treatment":[284],"related":[285],"toxicities,":[286],"patients":[288],"(19%)":[289],"G3":[290],"toxicities;":[291],"no":[294],"treatment-related":[295],"G4":[296],"G5":[298],"toxicities.":[299],"5":[304],"observed":[310],"\u22653":[314],"lines":[315],"(p":[319],"=":[320],"0.011)":[321],"tumors":[324],"who":[325],"negative":[328,362],"by":[329,345],"IHC.":[330],"Further":[331],"correlative":[332],"work":[333],"will":[334],"meeting.":[339],"Conclusions:":[340],"stratified":[344],"status,":[347],"MSI":[348],"vs":[349],"status":[351],"appears":[352],"correlated":[355],"even":[359],"tumors.":[363],"Responses":[364],"more":[370,373],"frequent":[371],"heavily":[374],"pretreated":[375],"patients,":[376],"a":[377],"finding":[378],"that":[379],"warrants":[380],"investigation.":[382],"Clinical":[383],"trial":[384],"information:":[385],"NCT02912572.":[386]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":4}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2019-06-07T00:00:00"}